Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
65.26
+1.75 (2.76%)
Feb 3, 2026, 3:00 PM CST
SHA:688621 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,016 | 1,077 | 930.98 | 676.39 | 492.86 | 346.82 |
Other Revenue | 1.61 | 1.61 | 1.14 | 0.21 | 0.79 | 0.54 |
| 1,018 | 1,078 | 932.12 | 676.61 | 493.65 | 347.36 | |
Revenue Growth (YoY) | -12.04% | 15.70% | 37.76% | 37.06% | 42.12% | 48.74% |
Cost of Revenue | 520.17 | 537.33 | 403.77 | 301.15 | 229.97 | 175.02 |
Gross Profit | 497.38 | 541.14 | 528.35 | 375.46 | 263.68 | 172.33 |
Selling, General & Admin | 159.8 | 150.44 | 153.24 | 110.81 | 85.63 | 52.87 |
Research & Development | 167.97 | 171.94 | 123.68 | 89.69 | 47.58 | 34.19 |
Other Operating Expenses | -4.9 | 0.76 | 0.2 | 0.16 | 0.04 | 0.04 |
Operating Expenses | 371.81 | 364.82 | 334.89 | 219.32 | 143.72 | 90.16 |
Operating Income | 125.57 | 176.32 | 193.46 | 156.14 | 119.97 | 82.17 |
Interest Expense | -16.25 | -16.11 | -12.18 | -9.7 | -3.56 | -1.04 |
Interest & Investment Income | 4.17 | 5.67 | 8.53 | 8.78 | 2.52 | 0.63 |
Other Non Operating Income (Expenses) | -1.09 | -2.66 | -2.47 | -0.96 | -0.72 | 0.26 |
EBT Excluding Unusual Items | 112.39 | 163.22 | 187.35 | 154.25 | 118.21 | 82.02 |
Gain (Loss) on Sale of Investments | -1.82 | -1.82 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.56 | -0.31 | -0.71 | -0.25 | -0.51 | -0.08 |
Other Unusual Items | 13.43 | 14.9 | 6.76 | 15.14 | 4.4 | 0.34 |
Pretax Income | 123.44 | 175.99 | 193.4 | 169.14 | 122.1 | 82.28 |
Income Tax Expense | -6.05 | 6.97 | 10.5 | 10.43 | 13.31 | 8.12 |
Earnings From Continuing Operations | 129.48 | 169.01 | 182.9 | 158.7 | 108.79 | 74.16 |
Minority Interest in Earnings | 3.52 | 8.4 | 1.86 | -2.23 | -3.13 | -1.7 |
Net Income | 133.01 | 177.41 | 184.76 | 156.47 | 105.66 | 72.46 |
Net Income to Common | 133.01 | 177.41 | 184.76 | 156.47 | 105.66 | 72.46 |
Net Income Growth | -39.92% | -3.98% | 18.08% | 48.09% | 45.81% | 52.88% |
Shares Outstanding (Basic) | 110 | 112 | 112 | 112 | 98 | 84 |
Shares Outstanding (Diluted) | 110 | 112 | 112 | 112 | 98 | 84 |
Shares Change (YoY) | -1.81% | 0.28% | 0.19% | 14.09% | 16.84% | -0.19% |
EPS (Basic) | 1.21 | 1.58 | 1.65 | 1.40 | 1.08 | 0.86 |
EPS (Diluted) | 1.21 | 1.58 | 1.65 | 1.40 | 1.08 | 0.86 |
EPS Growth | -38.81% | -4.24% | 17.86% | 29.80% | 24.80% | 53.16% |
Free Cash Flow | 64.09 | 1.54 | 19.9 | 0.09 | 3.29 | 35.96 |
Free Cash Flow Per Share | 0.58 | 0.01 | 0.18 | 0.00 | 0.03 | 0.43 |
Dividend Per Share | 0.163 | 0.163 | 0.165 | 0.429 | 0.189 | - |
Dividend Growth | -1.21% | -1.21% | -61.50% | 126.41% | - | - |
Gross Margin | 48.88% | 50.18% | 56.68% | 55.49% | 53.41% | 49.61% |
Operating Margin | 12.34% | 16.35% | 20.76% | 23.08% | 24.30% | 23.66% |
Profit Margin | 13.07% | 16.45% | 19.82% | 23.13% | 21.40% | 20.86% |
Free Cash Flow Margin | 6.30% | 0.14% | 2.14% | 0.01% | 0.67% | 10.35% |
EBITDA | 153.48 | 201.69 | 215.47 | 173.19 | 131.47 | 91.78 |
EBITDA Margin | 15.08% | 18.70% | 23.12% | 25.60% | 26.63% | 26.42% |
D&A For EBITDA | 27.91 | 25.38 | 22.01 | 17.05 | 11.5 | 9.61 |
EBIT | 125.57 | 176.32 | 193.46 | 156.14 | 119.97 | 82.17 |
EBIT Margin | 12.34% | 16.35% | 20.76% | 23.08% | 24.30% | 23.66% |
Effective Tax Rate | - | 3.96% | 5.43% | 6.17% | 10.90% | 9.87% |
Revenue as Reported | 1,018 | 1,078 | 932.12 | 676.61 | 493.65 | 347.36 |
Advertising Expenses | - | 0.58 | 1.69 | 1.17 | 1.13 | 0.79 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.